These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27854119)

  • 1. Clinical Applications of Genome Editing to HIV Cure.
    Wang CX; Cannon PM
    AIDS Patient Care STDS; 2016 Dec; 30(12):539-544. PubMed ID: 27854119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical applications of genome editing in HIV.
    Wang CX; Cannon PM
    Blood; 2016 May; 127(21):2546-52. PubMed ID: 27053530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
    Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
    Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
    Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
    J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART.
    Peterson CW; Younan P; Jerome KR; Kiem HP
    Gene Ther; 2013 Jul; 20(7):695-702. PubMed ID: 23364313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editing CCR5: a novel approach to HIV gene therapy.
    Cornu TI; Mussolino C; Bloom K; Cathomen T
    Adv Exp Med Biol; 2015; 848():117-30. PubMed ID: 25757618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.
    Dudek AM; Feist WN; Sasu EJ; Luna SE; Ben-Efraim K; Bak RO; Cepika AM; Porteus MH
    Cell Stem Cell; 2024 Apr; 31(4):499-518.e6. PubMed ID: 38579682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Strategies and Challenges of CCR5 Gene Editing in Hematopoietic Stem and Progenitor Cells for the Treatment of HIV.
    Karuppusamy KV; Babu P; Thangavel S
    Stem Cell Rev Rep; 2021 Oct; 17(5):1607-1618. PubMed ID: 33788143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designer Nucleases: Gene-Editing Therapies using CCR5 as an Emerging Target in HIV.
    Almeida MJ; Matos A
    Curr HIV Res; 2019; 17(5):306-323. PubMed ID: 31652113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in CCR5 regulation for HIV cure.
    Garg K; Khan AR; Taneja P
    Adv Protein Chem Struct Biol; 2021; 126():123-149. PubMed ID: 34090613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing.
    Knipping F; Newby GA; Eide CR; McElroy AN; Nielsen SC; Smith K; Fang Y; Cornu TI; Costa C; Gutierrez-Guerrero A; Bingea SP; Feser CJ; Steinbeck B; Hippen KL; Blazar BR; McCaffrey A; Mussolino C; Verhoeyen E; Tolar J; Liu DR; Osborn MJ
    Mol Ther; 2022 Jan; 30(1):130-144. PubMed ID: 34737067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome editing-based HIV therapies.
    Gu WG
    Trends Biotechnol; 2015 Mar; 33(3):172-9. PubMed ID: 25600622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
    Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
    Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
    Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
    Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mathematical model of HIV dynamics treated with a population of gene-edited haematopoietic progenitor cells exhibiting threshold phenomenon.
    Ratti V; Nanda S; Eszterhas SK; Howell AL; Wallace DI
    Math Med Biol; 2020 May; 37(2):212-242. PubMed ID: 31265056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.
    Allers K; Schneider T
    Curr Opin Virol; 2015 Oct; 14():24-9. PubMed ID: 26143158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure.
    Khan A; Paneerselvam N; Lawson BR
    Clin Immunol; 2023 Oct; 255():109741. PubMed ID: 37611838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.
    Ye C; Wang W; Cheng L; Li G; Wen M; Wang Q; Zhang Q; Li D; Zhou P; Su L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
    Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
    Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.